Medical Device Investing NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
Medical Device Investing NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
Medical Device Investing NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society Annual Meeting
Medical Device Investing NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
Medical Device Investing NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Medical Device Investing NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
Freegold Ventures Limited Announces Upsized Brokered Private Placement Financing from $30 Million to Up to $50 Million
